Ubs Asset Management Americas Inc Humanigen, Inc Transaction History

Ubs Asset Management Americas Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $54,288 - $102,717	-30,846 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $20,064 - $45,062	5,482 Added 21.61%	30,846 $114,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $23,820 - $71,623	4,017 Added 18.82%	25,364 $150,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $289,038 - $485,430	21,347 New	21,347 $371,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.